The association of Zika virus (ZIKV) infection with neurological complications during the recent worldwide outbreak and the lack of approved vaccines and/or antivirals have underscored the urgent need to develop ZIKV reverse genetic systems to facilitate the study of ZIKV biology and the development of therapeutic and/or prophylactic approaches. However, like with other flaviviruses, the generation of ZIKV full-length infectious cDNA clones has been hampered due to the toxicity of viral sequences during its amplification in bacteria. To overcome this problem, we have developed a nontraditional approach based on the use of bacterial artificial chromosomes (BACs). Using this approach, the full-length cDNA copy of the ZIKV strain Rio Grande do Norte Natal (ZIKV-RGN) is generated from four synthetic DNA fragments and assembled into the single-copy pBeloBAC11 plasmid under the control of the human cytomegalovirus (CMV) immediate-early promoter. The assembled BAC cDNA clone is stable during propagation in bacteria, and infectious recombinant (r)ZIKV is recovered in Vero cells after transfection of the BAC cDNA clone. The protocol described here provides a powerful technique for the generation of infectious clones of flaviviruses, including ZIKV, and other positive-strand RNA viruses, particularly those with large genomes that have stability problems during bacterial propagation.
Introduction
ZIKV is a mosquito-borne member of the Flavivirus genus within the Flaviviridae family that currently constitutes a global public health emergency 1 . Like other flaviviruses, ZIKV is an enveloped RNA virus with an icosahedral-like structure that contains a positive sense, singlestranded RNA molecule of about 10.8 kb (Figure 1 ) 2 . The viral genome encodes a large polyprotein of approximately 3,423 amino acids that is processed by viral and cellular proteases into three structural proteins (capsid [C], premembrane/membrane [prM/M], and envelope [E] ) that are involved in the formation of the viral particles and seven nonstructural (NS) proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) that participate in genome replication, virus assembly, and evasion of the host immune response (Figure 1 ) 3 .
Historically, ZIKV infection has been associated with a mild febrile illness 4, 5 . However, the explosive recent pandemic of ZIKV infections throughout South and Central America, the South Pacific, and the Caribbean 6, 7, 8 , and its association with the occurrence of Guillain-Barré syndrome and microcephaly 9, 10, 11, 12, 13 , have changed the historic perception and potentiated the relevance of ZIKV as an important human pathogen. In this sense, the development of molecular tools, such as infectious cDNA clones, will facilitate the study of viral pathogenesis and the development of genetically defined vaccines and the identification of antiviral drugs for the treatment of ZIKV infection. As described for other flaviviruses, the generation of ZIKV infectious clones is difficult due to the presence of cryptic bacterial promoters in the viral genome 14 that allow the leaky expression of toxic viral proteins during the propagation of the cDNA clones in bacteria using standard high-copy-number plasmids 15, 16, 17 . To overcome this toxicity problem, several nontraditional approaches have been implemented successfully in the last two years 18 . These include the use of low-copy-number plasmids 19, 20 , the insertion of introns to disrupt the toxic regions 21, 22, 23 , the in vitro ligation of cDNA fragments 24, 25 , mutational silencing of cryptic bacterial promoters present in the viral genome 26, 27 , infectious subgenomic amplicons (ISA) 28, 29 , the Gibson assembly method 30 , and the use of circular polymerase extension reaction (CPER) 31 .
Herein, we describe the detailed protocol for the engineering of a full-length cDNA clone of the ZIKV strain ZIKV-RGN 13 , using a BAC to overcome the toxicity problem, and the rescue of infectious rZIKV by direct transfection of the BAC cDNA clone into Vero cells 32 , a cell line approved by the Food and Drug Administration (FDA) for the development of human vaccines 33 . In this system, the full-length cDNA copy of the viral genome is assembled in the BAC plasmid pBeloBAC11 34 (Figure 2A) , a low-copy-number plasmid (one to two copies per cell) derived from the Escherichia coli F-factor 35 , which minimizes the toxicity of flavivirus sequences during its propagation in bacteria. The cDNA of the ZIKV genome is assembled in pBeloBAC11 under the control of the human CMV immediate-early promoter, to allow the expression of the viral (v)RNA in the nucleus of transfected cells by cellular RNA polymerase II, and flanked at the 3'-end by the hepatitis delta virus (HDV) ribozyme (RZ), followed by the sequences of the bovine growth hormone (BGH) termination and polyadenylation signals to produce synthetic RNAs bearing authentic 5'-and 3'-ends of the viral genome, respectively ( Figure 2B) . This cDNA-launched system results in the intracellular expression of capped viral RNA, allowing the recovery of infectious ZIKV without the need for an in vitro transcription step. The BAC approach provides a powerful methodology applicable to constructing stable and fully functional infectious cDNA clones for other flaviviruses, as well as other positive-stranded RNA viruses 36, 37, 38, 39, 40, 41 1. Grow a single colony of E. coli DH10B carrying the pBAC-ZIKV infectious clone in 5 mL of LB medium containing 12.5 µg/mL of chloramphenicol at 37°C for 8 h with gentle shaking (200-250 rpm). 2. Add 1 mL of bacterial culture (step 2.1) to 500 mL of LB with 12.5 µg/mL of chloramphenicol in a 2 L flask and grow the cells at 37°C for 14-16 h (till an OD 600 of 0.6-0.8). NOTE: Rich broths, such as Terrific Broth (TB), can produce extremely high cell densities, resulting in a lower yield and less purity of the BAC cDNA. 3. Purify the BAC infectious cDNA clone by alkaline lysis using a commercial kit specifically developed for BAC purification, following the manufacturer's specifications (see the 
Rescue of Infectious rZIKV from the BAC cDNA Clone by Transfection of Vero Cells
NOTE: Infectious rZIKV is recovered by the transfection of Vero cells with the pBAC-ZIKV cDNA clone, using a commercial cationic lipid transfection reagent (see the Table of Materials; Figure 3 ).
1. One day before transfection, plate on 6-well plates 5 x 10 5 Vero cells/well in growth medium (Dulbecco's modified Eagle's medium [DMEM] supplemented with 5% fetal bovine serum [FBS], 2 mM L-glutamine, and 1% nonessential amino acids) without antibiotics to raise 90% confluent cell monolayers by the time of transfection. NOTE: We recommend performing the virus rescues in triplicates.
Equilibrate serum-reduced medium (see the Table of Materials) at room temperature and prepare transfection mixtures in sterile microfuge tubes for each transfection sample as follows.
1. Add 4 µg of the BAC cDNA clone in 250 µL of serum-reduced medium and mix carefully, avoiding vortexing to prevent plasmid shearing. 2. In a separate tube, dilute 12 µL of transfection reagent (1 mg/mL) (see the Table of Materials) in 250 µL of serum-reduced medium, mix by vortexing, and incubate at room temperature for 5 min. 3. Combine the diluted BAC cDNA and the transfection reagent (with a 1:3 ratio of DNA:transfection reagent), mix carefully while avoiding vortexing, and incubate at room temperature for 20-30 min.
3. During the incubation period of the BAC cDNA/transfection reagentmixture,wash Vero cells with growth medium without antibiotics and leave the cells in 1 mL of fresh medium without antibiotics. NOTE: The addition of antibiotics during the transfection process may decrease transfection efficiency. 4. Distribute dropwise the 500 µL of the BAC cDNA/transfection reagent mixture (of step 3.2.3) onto the Vero cells, mix them by rocking the plate back and forth, and incubate the cells in a 5% CO 2 humidified incubator at 37 °C for 6 h. 5. Remove the transfection medium, add 2 mL of fresh growth medium with antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin), incubate the cells in a 5% CO 2 humidified incubator at 37 °C, and check every day for the induction of cytopathic effect (CPE). NOTE: ZIKV CPE is quite pronounced in Vero cells and it is characterized by the presence of rounded and birefringent cells that detach and float in the tissue culture supernatant. 6. Collect aliquots (100 µL) of the Vero cell tissue-culture supernatants (step 3.5) every 24 h to determine the efficiency of virus recovery by assessing the presence of ZIKV using a standard plaque assay on fresh Vero cells ( Figure 4A) . 7. After four to six days of transfection, when the CPE is around 50%-75% (Figure 4B) , collect the tissue culture supernatants in 15 mL conical tubes and centrifuge at 2,000 x g for 10 min at 4 °C to remove cellular debris. 8. Harvest the supernatants containing rZIKV and discard the cell pellets. Aliquot the supernatant in cryotubes and store them at -80 °C to further confirm the presence of rescued rZIKV.
Titration of Recovered rZIKV
1. A day before titration, seed on 12-well plates 2.5 x 10 5 Vero cells/well in growth medium to raise 90% confluent cell monolayers by the time of titration. NOTE: We recommend conducting the titration of the recovered rZIKV in triplicates. 2. Remove an aliquot of the supernatant from the freezer (step 3.8) and make serial 10-fold dilutions in growth medium without FBS. 3. Wash Vero cells 2x with phosphate-buffered saline (PBS) and add 200 µL/well of each virus dilution in triplicate. Place plates in a 5% CO 2 humidified incubator at 37 °C and rock every 15 min for a 90 min adsorption period. 4. Remove the viral inoculum, overlay the cells with 2 mL of growth medium containing 2% FBS, 1% DEAE-dextran, and 0.6% Agar Noble, and incubate at 37 °C under 5% CO 2 for 3-4 days. NOTE: It is possible to use agarose, methylcellulose, or other overlay media. The time for proper plaque formation will vary depending on the overlay used and the ZIKV strain. 5. Fix ZIKV-infected cells with 1 mL/well of 4% formaldehyde diluted in PBS at room temperature for 1 h, remove the overlay, and visualize the viral plaques by staining them with 0.1% crystal violet in 20% methanol at room temperature for 15 min. 1. Discard the crystal violet, wash 3x with water, allow the plates to dry, and manually count the plaques (Figure 4C, left panel) . Viral titer is calculated as plaque forming units per milliliter (PFU/ml).
6.
Alternatively, viral plaques can be visualized by immunostaining with the pan-flavivirus E protein mouse monoclonal antibody (mAb) 4G2 (Figure 4C, right panel) .
1. To evaluate ZIKV plaques by immunostaining, after the fixing and removal of the overlay agar as described above (in step 4.5), wash the cells 2x with PBS and permeabilize them by incubation with 200 µL/well of 0.5% Triton-X100 in PBS for 15 min at room temperature. 2. Remove the permeabilization solution, wash the cells 3x with PBS, and block them with 200 µL/well of blocking solution (10% FBS in PBS) for 1 h at room temperature. NOTE: Other standard blocking solutions (e.g., 2.5% BSA in PBS) can be used in this step. 3. Remove the blocking solution and incubate the cells with 200 µL/well of the pan-flavivirus E protein mAb 4G2 diluted in blocking solution (1 µg/mL) for 1 h at 37 °C. NOTE: Other mAb or polyclonal antibodies (pAb) can be used instead of 4G2 for the immunostaining and detection of viral plaques. 4. Wash the cells 3x with PBS, and incubate them with 200 µL of biotinylated anti-mouse secondary antibody diluted (following the manufacturer's recommendation) in blocking solution for 1 h at 37 °C. 5. Remove the secondary antibody, wash the cells 4x with PBS, and visualize the viral plaques using an avidin/biotin-based peroxidase kit following the manufacturer's specifications (see the Table of Materials).
Confirmation of Successful rZIKV Rescue NOTE:
To further confirm the identity of the rescued virus, ZIKV E protein expression is analyzed by immunofluorescence using the mouse mAb 1176-56 specific for ZIKV E protein (Figure 4D) . This mAb is specific for ZIKV E protein, contrary to the situation of the pan-flavivirus E protein mAb 4G2 (step 4.6.3). Alternatively, the virus identity can be confirmed by sequencing.
1. A day before immunofluorescence analysis, seed coverslips in 24-well plates containing 1 x 10 5 Vero cells/well in growth medium to raise 90% confluent cell monolayers by the time of infection. 2. Wash the cells 2x with PBS and infect them with a multiplicity of infection (MOI) of 0.5 PFU/cell of the rescued virus in growth medium without FBS (100 µL/well) in triplicate. Incubate the plates at 37 °C for 90 min. 3. After viral adsorption, remove the viral inoculum, add 0.5 mL of fresh growth medium with 2% FBS, and incubate the cells in a 5% CO 2 humidified incubator at 37 °C for 48 h. 4. Remove the tissue culture supernatant, fix the cells with 150 µL/well of 4% paraformaldehyde in PBS for 20 min at room temperature, and permeabilize the cells with 150 µL/well of 0.5% Triton-X100 in PBS for 15 min at room temperature. 5. After removing the permeabilization solution and washing the cells 3x with PBS, block the cells with 150 µL/well of blocking solution during 1 h at room temperature. NOTE: Cell scan be blocked with alternative blocking solutions (e.g., 2.5% BSA in PBS). 6. Remove the blocking solution and incubate the cells with 100 µL/well of mAb 1176-56, specific for ZIKV E protein, diluted in blocking solution
(1 µg/mL) for 1 h at 37 °C. 7. Wash the cells 3x with PBS, incubate them at room temperature for 1 h with 100 µL/well of Alexa Fluor 488-conjugated anti-mouse secondary antibody diluted (following the manufacturer's recommendation) in blocking solution, wash the cells extensively with PBS, and incubate them with 150 µL/well of 4',6'-diamidino-2-phenylindole (DAPI; 1 mg/mL) diluted 1:200 in PBS at room temperature for 10 min. 8. Wash the cells 3x with PBS, mount the coverslips on an antifade mounting medium (see the Table of Materials), and analyze the samples under a fluorescence microscope. NOTE: For long-term storage, store samples at 4 °C, protected from light.
Amplification and Generation of Viral Stocks NOTE:
Once the identity of the rescued virus is confirmed (section 5), amplify the virus on Vero cells and generate viral stocks for further studies.
a clear CPE (Figure 4B) , generated homogeneous plaques of about 2 mm in size (Figure 4C) , and its identity was confirmed by sequencing (data not shown) and immunofluorescence analysis using the mAb specific for ZIKV E protein, 1176-56 ( Figure 4D) . In vitro data indicate that the recovered rZIKV-RGN replicated efficiently in Vero cells and to levels compared to a natural ZIKV isolate 32 (data not shown). Overall, these results demonstrate that infectious rZIKV can be rescued from full-length cDNA clones assembled in a BAC. (Figure 1) and flanked by the indicated restriction sites, were generated by chemical synthesis and sequentially cloned into pBeloBAC11 to generate the infectious ZIKV cDNA clone pBAC-ZIKV. The full-length ZIKV infectious cDNA was assembled under the control of the human cytomegalovirus immediate-early promoter (CMV) and flanked at the 3'-end by the HDV ribozyme (RZ) and the bovine growth hormone (BGH) termination and polyadenylation sequences. The acronyms for the viral genes and regulatory elements are as described in Figure 1 . Please click here to view a larger version of this figure. 
Discussion
Infectious cDNA clones constitute essential molecular tools for basic research of RNA viruses and the development of vaccines and/or the identification of antiviral strategies. However, for many positive-stranded RNA viruses, including flaviviruses, the generation of infectious cDNA clones are difficult due to the instability of the cloned cDNAs when propagated in bacteria using standard high-copy-number plasmids. In the case of ZIKV and other flaviviruses, this instability is mainly due to the leaky expression of toxic viral proteins from cryptic bacterial promoters present in the viral genome 14, 15, 16, 17 . Here, we describe an alternative and powerful protocol to generate a stable ZIKV full-length infectious cDNA clone as a single plasmid, based on the use of the BAC plasmid pBeloBAC11 34 (Figure 2A) to overcome the toxicity problem, the use of the CMV promoter to allow the expression of the vRNA in the nucleus of transfected cells, and the HDV RZ to generate vRNAs with accurate 3'-ends ( Figure 2B) . Using this method, we have successfully generated a fully stable infectious clone of the ZIKV strain RGN that allows the efficient and reliable recovery of infectious rZIKV after the direct transfection of susceptible Vero cells (Figure 3 and Figure 4) .
A huge effort has been made in the last few years to overcome the instability problems associated with ZIKV infectious cDNA clones, and several approaches have been successfully implemented 18 , including the in vitro ligation of cDNA fragments 24, 25 , low-copy plasmids 19, 20 , the inactivation of cryptic bacterial promoters by the introduction of silent mutations 26, 27 , intron insertion 21, 22, 23 , the Gibson assembly method 30 , the ISA method 28, 29 , and the use of CPER 31 . Although these approaches overcome the toxicity problem and are useful to generate ZIKV infectious cDNA clones, some of them are laborious and present several disadvantages, including the need for in vitro ligation and transcription steps that reduce virus recovery efficiency or the introduction of a high number of silent mutations to inactivate cryptic bacterial promoter that could affect viral fitness, among others. The approach described in this protocol presents the following advantages. i) The BAC plasmid pBeloBAC11 34 has a strictly controlled replication, keeping one or two copies of plasmid per cell, which minimizes toxicity and allows stable maintenance in bacteria of instable cDNAs. ii) The propagation and modification of BAC plasmids are almost similar to those of conventional plasmids, considering the slight modifications described in this protocol to manipulate large-size BAC-DNA fragments and low-copy plasmids. Notably, the BAC cDNA clone can also be modified into E. coli by homologous recombination using the Red recombination system 42,43,44 . iii) The use of CMV promoter allows the intracellular expression of capped ZIKV vRNA and the recovery of infectious viruses without requiring an in vitro transcription step. iv) Infectious rZIKV is generated after the direct transfection of susceptible cells (e.g., Vero) with the BAC cDNA clone. Since DNA transfection in mammalian cells is more efficient than RNA transfection, the virus recovery efficiency with the BAC approach is higher than that observed using RNA transcripts, reducing the number of passages in culture cells to generate a viral stock and, consequently, limiting the introduction of unwanted mutations by cell culture adaptation.
